Vimta Labs reported strong Q4 with 31.4% revenue growth and a PAT margin of 19.1%. The company declared a ₹2 final dividend and proposed a 1:1 bonus share issue. Shares have gained over 1,100% in five years.
On Tuesday, as of 11:11 AM, share price of Vimta Labs Ltd was trading at ₹1,061 per share, up 3% from the previous close. Over the last six months, the stock has jumped 86%, while over the past five years it has gained more than 1,100%. Currently, the stock is trading 13% away from its 52-week high. On Monday, the company's board announced its financial results, declared a dividend, and proposed a bonus issue for its shareholders. As a result, the stock price of Vimta Labs is seen buzzing on the bourses.
Vimta Labs Limited, a prominent Contract Research and Testing Organisation in India, announced its financial results for the fourth quarter and the financial year that ended on March 31, 2025. The company's total income for Q4FY25 reached ₹96.08 crore, showing a growth of 31.4% compared to the ₹73.12 crore recorded in Q4FY24. EBITDA for Q4FY25 was ₹34.68 crore, with EBITDA margins at 36.1%, and PAT (Profit After Tax) was ₹18.32 crore, with a PAT margin of 19.1%.
For the financial year FY25, the total income was ₹348.22 crore, a 19.1% increase from the previous year's ₹292.31 million. EBITDA for FY25 stood at ₹126.19 crore, and PAT reached ₹66.76 crore. The Board of Directors has recommended a final dividend of ₹2 per equity share and also proposed a bonus share issue in the ratio of 1:1, subject to shareholder approval.
| Purpose | ₹ Per Share | Ex-date |
| Final Dividend | 2 | 11-Jul-24 |
| Final Dividend | 2 | 21-Jun-23 |
| Dividend | 2 | 16-Jun-22 |
| Dividend | 2 | 25-Jun-21 |
| Dividend | 2 | 18-Jul-19 |
Vimta Labs also announced its strategic expansion into Biologics Contract Research and Development (R&D) services. This new service line will focus on Novel Biologic Entities (NBEs), biosimilars, and peptide-based therapeutics, utilising both microbial and mammalian platforms. The company will offer end-to-end development capabilities, including clone and process development, drug product development, and biosimilarity assessment.
Commenting on results, Ms. Harita Vasireddi, Managing Director, Vimta Labs Limited, said: "We are pleased to report strong earnings and good growth this year, driven by growth in pharmaceutical services. Our pharma business benefited from increased traction in clinical and analytical services, supported by capacity expansion and deeper client engagements.”
Disclaimer: The article is for informational purposes only and not investment advice.
For android only